5.1 trillion US dollars of options will expire! The "Triple Witching Hour" of US stocks will hit tomorrow night, what impact will it have on the market?
According to derivative analysis company Asym 500 estimates, approximately $5.1 trillion of index, stocks, and ETF options will expire on Friday.
UBS Highlights 30 Stocks Poised for Potential Moves After the Fed's Expected Rate Cut
Express News | Bio Rad Laboratories Inc : RBC Raises Target Price to $446 From $401
Bio-rad Laboratories Insider Sold Shares Worth $989,815, According to a Recent SEC Filing
Top 20 Trading Volume | Nvidia rose 3.54%, with a trading volume exceeding 28.8 billion US dollars; will be included in the S&P 500 component stocks, Palantir surged more than 14%
Nvidia, the top trading volume in the US stock market on Monday, rose by 3.54%, with a turnover of $28.844 billion. Apple, ranked second, rose by 0.04%, with a turnover of $14.734 billion. Tesla, ranked third, rose by 2.63%, with a turnover of $14.618 billion.
Palantir Stock Rising. Its S&P 500 Addition Is 'Validation' for Bulls.
Palantir, Dell, Nvidia, Apple, Boeing, Oracle, and More Stock Market Movers
Effective before the market opens on September 23rd! Changes in S&P 500 constituent stocks: AI hot stocks and insurance stocks are coming.
①The 'AI hot stocks' Palantir Technologies Inc., Dell Technologies, and the leading company in the US insurance industry, Erie Indemnity Co., will join the S&P 500 index; ②These specific changes will take effect before the start of the US stock trading on September 23rd.
Palantir, Dell to Join S&P 500
Palantir Technologies, Dell Technologies, And S&P MidCap 400 Constituent Erie Indemnity Co. Set To Join S&P 500; Will Replace American Airlines Group, Etsy And Bio-Rad Laboratories
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Nephron Initiates Bio-Rad Laboratories(BIO.US) With Buy Rating, Announces Target Price $390
Nephron analyst Jack Meehan initiates coverage on $Bio-Rad Laboratories(BIO.US)$ with a buy rating, and sets the target price at $390.According to TipRanks data, the analyst has a success rate of 68.6
Jefferies Maintains Bio-Rad Laboratories(BIO.US) With Hold Rating, Raises Target Price to $340
Jefferies analyst Brandon Couillard maintains $Bio-Rad Laboratories(BIO.US)$ with a hold rating, and adjusts the target price from $315 to $340.According to TipRanks data, the analyst has a success
Wells Fargo Initiates Coverage On Bio-Rad Laboratories With Equal-Weight Rating, Announces Price Target of $340
Bio-Rad's Management to Participate in Fireside Chat During Wells Fargo's 2024 Healthcare Conference
Express News | Bio Rad Laboratories Shares Down 1.1%; Co Appoints Jon Divincenzo President, COO
Bio-Rad Appoints Jon DiVincenzo As President And Chief Operating Officer, Effective September 9, 2024, Replacing Andy Last, Who Is Retiring
Express News | Bio-Rad Appoints Jon Divincenzo President, Chief Operating Officer
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Maintains Target Price $401
RBC Capital analyst Conor McNamara maintains $Bio-Rad Laboratories(BIO.US)$ with a buy rating, and maintains the target price at $401.According to TipRanks data, the analyst has a success rate of 43.0
Bio-Rad Laboratories (BIO) Receives a Buy From RBC Capital